Prime Medicine, Inc. (PRME) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Prime Medicine, Inc. stock $1.98, price $4.19, that is 52.7% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Prime Medicine, Inc.
PRME · USFar too expensive (fair value 53% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
49‑month range $1.15 – $21.12 · fair‑value band $1.48 – $2.47 · the $4.19 price screens above the $1.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Prime Medicine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
Show moreShow less
Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs.
In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor.
The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Stock analysis
Prime Medicine, Inc. (PRME) currently trades at $4.19, while our estimate is $1.98, 53% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.48 (bear) to $2.47 (bull), the price of $4.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Prime Medicine, Inc. reported revenue of $4.6M in FY2025 versus $0 in FY2021. Reported net income was −$201M in FY2025.
Key figures
Market cap $932M Small · EPS (TTM) $−0.9700 · Return on equity −207% · Return on assets (EBIT) −59.0% (5-year average) · Operating margin −2,584% · Revenue (TTM) $7.1M · Revenue growth (YoY) +244% · Free cash flow −$167M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 7 out of 100 (medium confidence).
What moves the price
The share trades about 22% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −53%, PRME screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
- Prime Medicine stock jumps 8% after FDA clears PM647 trial
- Prime Drink Group Provides Bi-Weekly MCTO Status Report
Compare Prime Medicine, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs PRME |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs PRME |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs PRME |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs PRME |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs PRME |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs PRME |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs PRME |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs PRME |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs PRME |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs PRME |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Prime Medicine, Inc. (PRME) overvalued or undervalued?
What is the fair value of PRME?
What is the quality score of PRME?
What is the price target for Prime Medicine, Inc. (PRME)?
What is the Prime Medicine, Inc. stock forecast for 2026?
What is the revenue of Prime Medicine, Inc. (PRME)?
What is the intrinsic value of Prime Medicine, Inc. (PRME)?
Is Prime Medicine, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of PRME?
How much is Prime Medicine, Inc. worth?
What do the bullish and bearish scenarios say about PRME?
How solid is the balance sheet of Prime Medicine, Inc. (PRME)?
How far is PRME from its 52-week high?
Which stocks are comparable to Prime Medicine, Inc.?
Is Prime Medicine, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Prime Medicine, Inc. (PRME)?
What should I pay attention to with Prime Medicine, Inc. right now?
Key figures of Prime Medicine, Inc.
How large is the market capitalisation of Prime Medicine, Inc. (PRME)?
What are the earnings per share of Prime Medicine, Inc. (PRME)?
What is the return on equity of Prime Medicine, Inc. (PRME)?
What is the EBIT return on assets of Prime Medicine, Inc. (PRME)?
What is the operating margin of Prime Medicine, Inc. (PRME)?
How fast is revenue growing at Prime Medicine, Inc. (PRME)?
How much free cash flow does Prime Medicine, Inc. (PRME) generate?
How much net debt does Prime Medicine, Inc. (PRME) carry?
Watch Prime Medicine, Inc. in the live analysis
One click puts Prime Medicine, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.